Valproic acid - Cerebral Therapeutics
Alternative Names: CT-010Latest Information Update: 29 Mar 2024
At a glance
- Originator University of Colorado at Anschutz Medical Campus
- Developer Cerebral Therapeutics
- Class Antiepileptic drugs; Antimigraines; Antineoplastics; Antithrombotics; Nootropics; Pentanoic acids; Small molecules; Vascular disorder therapies
- Mechanism of Action 4-aminobutyrate transaminase inhibitors; Glutamate decarboxylase stimulants; Histone deacetylase inhibitors; Neurotransmitter modulators; Plasminogen activator inhibitor-1 inhibitors; Plasminogen activators; Sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Epilepsy
Most Recent Events
- 01 Mar 2024 Cerebral Therapeutics terminates phase I/II open-label extension trial in Epilepsy (Treatment-experienced, In adults, In the elderly) in Australia and Israel (Intraventricular) due to company decision (NCT04529954)
- 01 Mar 2024 Cerebral Therapeutics terminates phase-II trial in Epilepsy (Treatment-resistant, In adults, In the elderly) in Australia and Israel (Intraventricular) due to company decision(NCT04153175)
- 28 Jun 2022 Cerebral Therapeutics plans a phase III trial for Epilepsy